This study systematically elucidates the oncogenic role of HSP60 in PCa progression, delineates its mechanism in metabolic reprogramming via p53 suppression, and pioneers an EVs-based siRNA delivery system (siRNA@EVs) as a promising therapeutic approach. The gene discussed is TP53; the disease is posterior cortical atrophy.